<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541628</url>
  </required_header>
  <id_info>
    <org_study_id>SIG-001-121</org_study_id>
    <nct_id>NCT04541628</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A</brief_title>
  <official_title>A Phase 1/2 Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of SIG-001 in Adult Patients With Severe or Moderately-Severe Haemophilia A Without Inhibitors (SIG-001-121)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sigilon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sigilon Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SIG-001-121 is a first-in-human (FIH), phase 1/2, multi-centre, open-label, dose escalation&#xD;
      study to assess the safety, tolerability, and preliminary efficacy of SIG-001 in adults with&#xD;
      severe or moderately severe haemophilia A without inhibitors. Up to three dose cohorts (3&#xD;
      patients each) are planned. Cohort expansions (up to 3 additional patients) may be triggered&#xD;
      to collect additional information about safety and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporary enrolment halt&#xD;
  </why_stopped>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and proportion of participants with treatment emergent adverse events (TEAEs) overall and by dose/cohort.</measure>
    <time_frame>From SIG-001 administration until study completion (5 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and proportion of participants with serious treatment emergent adverse events (TEAEs) overall and by dose/cohort.</measure>
    <time_frame>From SIG-001 administration until study completion (5 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of participants with inhibitor titer values assessed by Nijmegen Bethesda Assay overall and by dose/cohort.</measure>
    <time_frame>From SIG-001 administration until study completion (5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVIII activity levels assessed by one-stage and chromogenic assays overall and by dose/cohort.</measure>
    <time_frame>From SIG-001 administration until study completion (5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding Rate (ABR) for all bleeds following SIG-001 administration presented by bleed type and location.</measure>
    <time_frame>From SIG-001 administration until study completion (5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of replacement FVIII therapies administered overall and by dose/cohort.</measure>
    <time_frame>From SIG-001 administration until study completion (5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>SIG-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B-Domain Deleted Human Factor VIII (BDD-hFVIII) Producing Spheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>SIG-001</intervention_name>
    <description>Laparoscopic administration of SIG-001 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce BDD-hFVIII.</description>
    <arm_group_label>SIG-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males aged 18 years or older&#xD;
&#xD;
          -  Diagnosis of Haemophilia A defined as ≤2% FVIII activity&#xD;
&#xD;
          -  Greater than 150 exposure days to treatment with FVIII products&#xD;
&#xD;
          -  Use of reliable barrier contraception if applicable&#xD;
&#xD;
          -  Normal levels of von Willebrand factor (VWF) antigen&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Willing to withdraw from FVIII prophylaxis during specified periods in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥35&#xD;
&#xD;
          -  Current FVIII inhibitors (&gt;0.6 Nijmegen Bethesda Units/mL) or prior Immune Tolerance&#xD;
             Induction (ITI)&#xD;
&#xD;
          -  History of allergic reaction or anaphylaxis to recombinant FVIII products or SIG-001&#xD;
             components&#xD;
&#xD;
          -  Evidence of any bleeding disorder in addition to haemophilia A&#xD;
&#xD;
          -  Abnormal laboratory values as defined in the protocol&#xD;
&#xD;
          -  Active infection with Hepatitis B or Hepatitis C virus or currently managed with&#xD;
             antiviral medications for Hepatitis B or C&#xD;
&#xD;
          -  Uncontrolled HIV infection&#xD;
&#xD;
          -  Active alcoholism or drug addiction during the 12 months before the screening visit&#xD;
&#xD;
          -  Active malignancy or history of malignancy in the 5 years prior to study entry&#xD;
&#xD;
          -  Participation in another investigational medicine or device study&#xD;
&#xD;
          -  Prior administration of a gene therapy product&#xD;
&#xD;
          -  Significant underlying disease or comorbidities that are a contraindication for&#xD;
             general anaesthesia or laparoscopic procedure&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilia A</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

